Executive Summary

The Colon Capsule Endoscopy Market was valued at 163.7 USD Million in 2025 and is projected to reach 366.7 USD Million by 2035, registering a CAGR of 8.4% over the forecast period.

Reimbursement is the strongest lever: CMS covers colon capsule endoscopy under CPT 91113 via LCD L38571, effective April 2026, while China’s NMPA advanced AI-assisted endoscopy evaluation guidance in June 2026. The capsule clears through FDA’s 510(k)/De Novo device pathway rather than the BLA route reserved for biologics, and imaging data handling sits within HIPAA and GDPR.

North America held 43.5% of the market in 2025 and Europe followed at 28.0%, where devices carry CE marking under the EU MDR and reimbursement runs through national HTA review. The camera capsule leads by component and hospitals lead by end-user setting.

Medicare explicitly excludes colon capsule endoscopy from colorectal cancer screening under CDC-tracked guidance, limiting reimbursed use to rescue and high-risk testing. Competition rests on the single-use camera capsule as a recurring consumable.

Key Takeaways

• A CAGR of 8.4% carries the market from USD 163.70 Million in 2025 to USD 366.73 Million in 2035.
• Camera Capsule (Capsule Endoscope) holds the largest position on component.
• On end user, the leading category is Hospitals.
• North America accounted for 43.5% of the market in 2025.
• 10 suppliers are profiled.

Market Definition and Scope

The Colon Capsule Endoscopy Market covers swallowable camera capsules (single- and dual-camera, CMOS or CCD sensor), wearable data recorders, workstation and image-reading software, and patency, booster and bowel-preparation accessories used to visualize the colon without sedation. It spans obscure gastrointestinal bleeding, Crohn’s disease and small intestine tumor indications across hospitals, ambulatory surgical centers, diagnostic and imaging centers, and academic and research institutes.

Excluded are conventional optical colonoscopy and flexible sigmoidoscopy systems, which rely on inserted scopes rather than an ingested capsule, and upper gastrointestinal capsule systems designed solely for esophageal or gastric visualization.

Growth Drivers and Restraints

Medicare’s 2026 coverage decision opens a reimbursement pathway for colon capsule endoscopy

CMS established Medicare coverage for colon capsule endoscopy under CPT 91113, one of the CPT/HCPCS codes CMS uses to define payable procedures, through Local Coverage Determination L38571, effective April 2026. The policy covers the procedure as a secondary test after incomplete optical colonoscopy or as a primary test in patients at major risk for colonoscopy with a positive fecal occult blood or stool DNA result. It applies across Wellpoint Federal’s MAC jurisdictions, including New York, Massachusetts and Connecticut. A parallel Noridian LCD covering Alaska, Washington and seven other western states was retired in September 2025 and folded into a unified JE determination, consolidating coverage administration and reducing the jurisdictional friction hospitals faced when billing across MAC boundaries. The capsule itself reaches the US market through FDA’s 510(k) or De Novo clearance route for endoscopic imaging devices, a review track distinct from the CMS payment determination that now governs reimbursement.

AI-assisted image review is extending from radiology into endoscopy under Chinese regulatory guidance

China’s National Medical Products Administration released draft guidance in June 2026 on clinical evaluation of Class III AI-assisted diagnostic devices, the classification covering AI endoscopy reading software, alongside a run of 2026 Class III registrations that extended AI device approvals from radiology into pathology and endoscopy. The National Health Commission’s November 2025 “Artificial Intelligence+” plan set a 2027 target for AI diagnostic tools nationwide and scheduled pilots across 50 hospitals and 500 township clinics between April and December 2026, a channel through which capsule-reading workstation software can reach primary-level institutions that lack dedicated gastroenterologists. Licensing this software into the United States would put patient imaging data under HIPAA, and the Biosecure Act’s scrutiny of Chinese-origin health technology adds a further diligence layer before US health systems could deploy it. Any parallel rollout into Europe would carry GDPR health-data obligations on top.

The camera capsule’s single-use design ties revenue to procedure volume rather than one-time equipment sales

The camera capsule leads the component segment because it is consumed on every procedure, while data recorders and workstations are reusable capital equipment purchased far less often. As CPT 91113 billing under LCD L38571 broadens the pool of covered procedures, capsule consumption scales with reimbursed volume rather than with new equipment placements, reinforcing hospitals’ position as the dominant end-user setting for repeat purchasing.

Medicare reimbursement excludes colon capsule endoscopy from colorectal cancer screening

LCD L38571 states explicitly that colon capsule endoscopy “is not a Medicare Benefit for colorectal cancer screening, regardless of family history or other risk factors,” and bars its use alongside CT colonography or in patients with obstruction, stricture, fistula, cardiac pacemakers or swallowing disorders. Reimbursed use is confined to rescue testing after an incomplete colonoscopy or to high-risk primary cases referred by a board-certified gastroenterologist. That caps the addressable Medicare volume well below the population the CDC tracks through its colorectal cancer surveillance programs.

Coverage remains fragmented across Medicare jurisdictions and regulatory regimes

LCD L38571 applies only to Wellpoint Federal’s ten-state jurisdiction, and the equivalent Noridian determination covering Alaska, Idaho, Oregon, Washington and six other western states was retired in September 2025 and consolidated into a single JE policy. Hospitals and ambulatory surgical centers outside an active determination’s jurisdiction face inconsistent reimbursement, slowing adoption in MAC regions where colon capsule endoscopy has no standing local coverage policy. Outside the United States, market access turns on national HTA review rather than a single federal decision. European distribution additionally requires EU MDR conformity, and IVDR certification where a companion stool-based test is co-marketed, a compliance layer the US 510(k)/CMS pathway does not impose.

Market Trends

AI-assisted capsule image review is moving from radiology pilots into endoscopy workflows in China

China’s National Medical Products Administration issued draft clinical-evaluation guidance for Class III AI-assisted diagnostic devices in June 2026, a classification extending into endoscopy alongside a run of 2026 device registrations. The National Health Commission’s November 2025 implementation plan schedules pilots across 50 hospitals and 500 township clinics between April and December 2026, aiming to place AI diagnostic support at primary-level institutions by 2030. A comparable workstation marketed in the United States would instead route through the FDA’s 510(k) or De Novo clearance pathway, with the underlying image-handling software also subject to 21 CFR Part 11 electronic-record controls and HIPAA-governed patient data protection. Capsule-reading workstation software is positioned to absorb this shift first.

Colon capsule endoscopy is being adopted as a non-invasive alternative within gastrointestinal diagnostic pathways

Capsule ingestion requires no sedation and no scope insertion, and clinicians increasingly use it as a non-invasive alternative within gastrointestinal diagnostic pathways rather than reserving it for rescue testing alone. Capsule endoscopy systems reached the US market through the FDA’s 510(k) clearance pathway, and CDC colorectal cancer screening guidance continues to shape which non-invasive modalities gastroenterologists offer patients who decline or cannot complete optical colonoscopy. The shift favors ambulatory surgical centers and diagnostic imaging centers, which can offer the procedure without the recovery infrastructure optical colonoscopy requires, and it widens the pool of patients willing to complete bowel preparation and undergo repeat surveillance over the forecast period.

Medicare coverage determinations are consolidating into fewer, broader jurisdictional policies

CMS’s Local Coverage Determination L38571 took effect in April 2026 across ten Wellpoint Federal states, while the equivalent Noridian determination for ten western states was retired in September 2025 and folded into a single JE policy. That consolidation reduces the number of distinct coverage documents hospitals must track and points toward more uniform national reimbursement terms for CPT 91113, paired with its corresponding HCPCS supply code, as additional Medicare Administrative Contractors align their policies. The pattern echoes the health technology assessment model used by bodies such as NICE, where one national determination replaces a patchwork of regional judgments.

Regional Analysis

North America

North America accounted for 43.5% of the market in 2025, the largest of the five regions. Volume here is capped by payer policy: CMS Local Coverage Determination L38571 reimburses colon capsule endoscopy under CPT 91113 only after an incomplete optical colonoscopy or in patients judged too high-risk for sedation, and it explicitly excludes colorectal-cancer screening use. The test remains a rescue tool under Medicare, not a front-line screen. Capsule-reading platforms sold into US hospital networks reach market through the FDA 510(k) pathway, and once installed, their electronic records fall under 21 CFR Part 11 controls and their image data under HIPAA.

Europe

Europe’s 28.0% share in 2025 rests on the deepest published clinical record for the procedure. The UK’s CAP ACCESS study, run to ICH GCP standards, followed 2,508 NHS England and NHS Scotland patients across 12 centres between June 2021 and June 2023, and colon capsule endoscopy identified 4,898 polyps, including 829 significant polyps against 289 found later at optical endoscopy. NICE’s April 2025 draft health technology assessment separately priced the PillCam COLON 2 capsule at £460.00 per use and its reusable sensor belt at £307.28 a year. Devices sold across the bloc carry certification under the EU Medical Device Regulation rather than the pre-2021 directive it replaced, a heavier clinical-evidence burden that keeps new entrants scarce.

Asia Pacific

Asia Pacific’s capsule supply is increasingly domestic. Ankon Medical Technologies and Jinshan Science and Technology, both headquartered in China, design and manufacture capsule endoscopes inside the country rather than importing from Japan or Korea, letting Chinese suppliers compete on price against Olympus and Fujifilm. India’s Central Drugs Standard Control Organisation licenses capsule endoscopy systems as Class C devices, a lower evidentiary bar than the FDA 510(k) clearance the same manufacturers would need to enter the US directly. Proposed Biosecure Act restrictions on federally linked providers’ use of named Chinese biotech suppliers stand as a further obstacle should Ankon or Jinshan pursue US distribution rather than regional sales.

Latin America

Brazil regulates the capsule-reading workstation and its software as Software as a Medical Device under ANVISA’s RDC No. 657/2022, written before continuously learning image-review algorithms became common. ANVISA has placed a revision of that rule on its stated 2026-2027 agenda, leaving the software layer under a framework the regulator itself intends to update.

Middle East & Africa

Gulf healthcare systems typically register imaging and endoscopy devices only after US FDA clearance or EU CE marking, so a colon capsule system’s regional rollout follows rather than parallels its American and European launch. Device submissions built on Gulf trial sites are generally run to ICH GCP standards specifically so the same dataset can support both an FDA filing and an EU technical file, tying Middle Eastern hospital-network procurement to approval timelines set elsewhere.

Segment Analysis

Technology

• CMOS – An image sensor built with complementary metal-oxide-semiconductor circuitry that converts light into electronic signals inside the capsule’s camera module for transmission to an external recorder
• CCD – A charge-coupled device image sensor that captures light through an array of photosensitive elements and shifts the resulting charge across the chip for readout in capsule camera systems

Application

• Obscure Gastrointestinal Bleeding – A clinical condition of recurrent or persistent GI bleeding with no source identified by standard endoscopy, evaluated using capsule imaging of the colon

• Overt Obscure GI Bleeding
• Occult Obscure GI Bleeding
• Crohn’s Disease – A chronic inflammatory bowel disease causing patchy inflammation anywhere along the digestive tract, monitored non-invasively with colon capsule endoscopy to assess mucosal healing

• Ileal Crohn’s Disease
• Colonic Crohn’s Disease
• Ileocolonic Crohn’s Disease
• Small Intestine Tumors – Benign or malignant growths arising in the small bowel that colon capsule endoscopy helps detect by visualizing regions difficult to reach with conventional scopes
• Benign Tumors

• Polyps
• Lipomas
• Leiomyomas
• Malignant Tumors

• Adenocarcinoma
• Carcinoid Tumors
• Lymphoma
• Gastrointestinal Stromal Tumors

Obscure gastrointestinal bleeding is the application most tightly linked to reimbursed use, since US Medicare coverage for colon capsule endoscopy conditions payment on evidence of lower GI bleeding found after an incomplete colonoscopy or in a patient too high-risk for one. That coverage language embeds bleeding work-up as the primary billable pathway, ahead of Crohn’s disease surveillance and small intestine tumor detection, neither of which carries an equivalent coverage determination. Crohn’s disease monitoring is the fastest-growing application, pulled by mucosal healing’s shift from a research endpoint to a routine treatment-monitoring target that favors repeat non-invasive imaging over serial optical colonoscopy.

By Component

• Camera Capsule (Capsule Endoscope) (largest) – A swallowable pill-sized device containing miniature cameras, LEDs, and a battery that captures images of the colon as it passes through the digestive tract

• Single-Camera Capsule
• Dual-Camera Capsule

• Data Recorder – A wearable belt or vest-mounted unit worn by the patient that receives and stores image transmissions from the capsule via wireless sensors during the procedure
• Workstation & Software – A computer system with proprietary software used by clinicians to download, reconstruct, view, and annotate the capsule-acquired images into a reviewable colon examination report

• Workstation Hardware
• Image Reading & Reporting Software
• Accessories (Patency/Booster Capsules) – Dissolvable test capsules and bowel-preparation aids used to verify safe passage through the gastrointestinal tract and to propel the capsule through the colon

• Patency Capsule
• Booster Capsule
• Sensor Belt/Array
• Bowel Preparation Kit

The camera capsule leads By Component in 2025, ahead of the data recorder, workstation and software, and patency and booster accessories. It is a single-use item repurchased on every procedure, while the recorder and workstation are capital equipment a site buys once and depreciates over years, tying capsule revenue to procedure volume rather than site count. Accessories are growing fastest, as incomplete-procedure rates push demand for booster capsules that complete colonic transit. CAP ACCESS attributed 37% of missed significant polyps to incomplete procedures, the failure mode booster capsules are designed to close.

By End User

• Hospitals (largest) – Inpatient and outpatient medical facilities that perform colon capsule endoscopy procedures for patients referred for colorectal screening or diagnostic evaluation

• Public/Government Hospitals
• Private Hospitals

• Ambulatory Surgical Centers – Outpatient facilities equipped for same-day procedures where patients swallow the capsule endoscope and are discharged without overnight admission
• Diagnostic & Imaging Centers – Standalone facilities specializing in imaging and diagnostic tests, including capsule endoscopy readings, for physicians who refer patients externally

• Standalone Diagnostic Centers
• Hospital-based Diagnostic Centers
• Academic & Research Institutes – Universities and research organizations that use colon capsule endoscopy in clinical trials, technology validation studies, and training programs for medical practitioners

Hospitals lead By End User in 2025, holding the established GI endoscopy infrastructure, on-site specialist coverage, and the incomplete-colonoscopy referral relationships that anchor US Medicare reimbursement for the procedure. Diagnostic and imaging centers and ambulatory surgical centers are gaining share fastest, since capsule ingestion needs no sedation, endoscopy suite, or procedure room, letting the test move to lower-cost outpatient settings without the capital equipment hospitals already carry. That mirrors the broader shift of gastrointestinal procedures toward ambulatory and homecare delivery.

Competitive Landscape

The colon capsule endoscopy market is led by a group of established gastrointestinal-device manufacturers rather than a single dominant supplier: Medtronic, Olympus Corporation, Fujifilm Holdings Corporation, CapsoVision, IntroMedic, Ankon Medical Technologies, Jinshan Science and Technology, RF System Lab, Check-Cap, and AnX Robotica all compete in the category. Competition centres on consumable lock-in. Once a hospital or diagnostic centre owns the reusable data recorder and workstation, its GI service keeps buying that vendor’s single-use capsules and patency accessories for every subsequent procedure. Regulatory and reimbursement status is the second axis of rivalry. In the United States, a device’s standing under the CMS coverage rule that pays only for post-incomplete-colonoscopy and high-risk-patient use, together with its FDA device classification, determines which suppliers a hospital GI department can put in front of a Medicare-covered patient at all. Manufacturing base separates the field further. Ankon Medical Technologies and Jinshan Science and Technology are building capsule-manufacturing capacity inside China, alongside the longer-established Japanese and US suppliers in the group.

Strategic Outlook

The clearest whitespace is the incomplete-colonoscopy segment itself: as more endoscopy units document failed completions, gastroenterology practices gain a reimbursable bridge to colon capsule under the existing CMS pathway, provided image-reading workstations keep polyp-detection accuracy close to optical endoscopy rather than trailing it.

By 2035, competitive weight is likely to shift from the capsule itself toward the recorder and workstation software that reads it, since accuracy and reporting speed, not the pill, are what a hospital GI department will compare when it standardises on a single vendor.

Colon Capsule Endoscopy Market Report Scope